Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 71.79% is 21% above its 5-year average of 59.27%, near the high end of its 5-year range (31.96%–78.41%).
1.52% below its 12-month average of 72.90%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 78.41%.
GROSS MARGIN
71.79%
GROSS MARGIN AVG TTM
72.90%
GROSS MARGIN AVG 3Y
68.33%
GROSS MARGIN AVG 5Y
59.27%
GROSS MARGIN AVG 10Y
52.03%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1.52%
CURRENT VS 3Y AVG
+5.06%
CURRENT VS 5Y AVG
+21.13%
CURRENT VS 10Y AVG
+37.98%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.38%
median of 836 covered companies
CURRENT VS SECTOR MEDIAN
+77.79%
vs the sector median at left
Profound Medical Corp.
Market Cap
$222.75M
Gross Margin
71.79%
TTM Avg
72.90%
3Y Avg
68.33%
5Y Avg
59.27%
Market Cap
$223.48M
Gross Margin
94.68%
TTM Avg
99.69%
3Y Avg
74.84%
5Y Avg
66.56%
Market Cap
$216.82M
Gross Margin
87.24%
TTM Avg
79.57%
3Y Avg
65.64%
5Y Avg
63.99%
Market Cap
$214.64M
Gross Margin
64.24%
TTM Avg
63.06%
3Y Avg
61.57%
5Y Avg
61.22%
Market Cap
$214.30M
Gross Margin
-31952.78%
TTM Avg
-15926.39%
3Y Avg
-7913.19%
5Y Avg
-5242.13%
Market Cap
$232.32M
Gross Margin
71.12%
TTM Avg
81.41%
3Y Avg
85.88%
5Y Avg
90.00%
Market Cap
$233.51M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$234.75M
Gross Margin
99.39%
TTM Avg
50.00%
3Y Avg
25.00%
5Y Avg
25.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Profound Medical Corp. (PROF) | $222.75M | 71.79% | 72.90% | 68.33% | 59.27% |
| Keros Therapeutics, Inc. (KROS)vs › | $223.48M | 94.68% | 99.69% | 74.84% | 66.56% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $216.82M | 87.24% | 79.57% | 65.64% | 63.99% |
| Biodesix, Inc. (BDSX)vs › | $229.55M | 82.50% | 79.64% | 73.94% | 65.24% |
| Niagen Bioscience Inc (NAGE)vs › | $214.64M | 64.24% | 63.06% | 61.57% | 61.22% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $214.30M | -31952.78% | -15926.39% | -7913.19% | -5242.13% |
| MacroGenics, Inc. (MGNX)vs › | $232.32M | 71.12% | 81.41% | 85.88% | 90.00% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $233.51M | 0.00% | 0.00% | 0.00% | 0.00% |
| BioAge Labs Inc. (BIOA)vs › | $234.75M | 99.39% | 50.00% | 25.00% | 25.00% |
| InflaRx N.V. (IFRX)vs › | $235.67M | -24677.94% | -13289.35% | -6830.59% | -4553.73% |
Gross Margin
71.8%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 78.41% |
| 2026-03-31 | 71.80% |
| 2025-12-31 | 66.77% |
| 2025-09-30 | 74.32% |
| 2025-06-30 | 73.18% |
| 2025-03-31 | 70.70% |
| 2024-12-31 | 70.94% |
| 2024-09-30 | 63.14% |
| 2024-06-30 | 63.64% |
| 2024-03-31 | 60.18% |
| 2023-12-31 | 49.23% |
| 2023-09-30 | 61.34% |
| 2023-06-30 | 65.54% |
| 2023-03-31 | 64.25% |
| 2022-12-31 | 44.47% |
| 2022-09-30 | 53.56% |
| 2022-06-30 | 46.22% |
| 2022-03-31 | 31.96% |
| 2021-12-31 | 49.80% |
| 2021-09-30 | 38.90% |
| 2021-06-30 | 46.29% |
| 2021-03-31 | 35.44% |
| 2020-12-31 | 39.69% |
| 2020-09-30 | 65.82% |
| 2020-06-30 | 40.55% |
| 2020-03-31 | 38.10% |
| 2019-12-31 | 57.45% |
| 2019-09-30 | 42.10% |
| 2019-06-30 | 57.49% |
| 2019-03-31 | 63.86% |
| 2018-12-31 | 30.86% |
| 2018-09-30 | 20.74% |
| 2018-06-30 | 40.82% |
| 2018-03-31 | 38.60% |
| 2017-12-31 | 43.72% |
| 2017-09-30 | 19.09% |
| 2017-06-30 | 50.75% |
| 2017-03-31 | 47.39% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
